Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Capital Expenditures (2017 - 2025)

Puma Biotechnology's Capital Expenditures history spans 6 years, with the latest figure at -$102000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 410.0% year-over-year to -$102000.0; the TTM value through Dec 2025 reached $5000.0, changed N/A, while the annual FY2025 figure was $5000.0, N/A changed from the prior year.
  • Capital Expenditures reached -$102000.0 in Q4 2025 per PBYI's latest filing, down from $26000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $61000.0 in Q1 2025 to a low of -$102000.0 in Q4 2025.
  • Average Capital Expenditures over 3 years is $2000.0, with a median of $20000.0 recorded in 2024.
  • The largest YoY upside for Capital Expenditures was 0.0% in 2025 against a maximum downside of 410.0% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $26000.0 in 2023, then crashed by 176.92% to -$20000.0 in 2024, then crashed by 410.0% to -$102000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Capital Expenditures are -$102000.0 (Q4 2025), $26000.0 (Q3 2025), and $20000.0 (Q2 2025).